Chungui International BioTech filed for an initial public offering on the Nasdaq Capital Market under the ticker CQFT. The company plans to offer 3,000,000 ordinary shares at an expected price of $5.00 per share, targeting gross proceeds of $15 million. The Cayman Islands holding company operates primarily through China-based subsidiaries focused on biofermentation technologies for cinnamon-based health products.

Business Description

Chungui International BioTech develops and commercializes biofermented health and wellness products derived from Six-Year-Old Aged Cinnamon. Using its proprietary “Microbial Fan’s Method,” the company claims to enhance the release and bioavailability of core cinnamon components while shortening fermentation cycles and reducing environmental impact. Its flagship category is a medicinal-food homologous natural active nutritional wine, targeting both premium and mass-market consumers through six product systems.

The company emphasizes a growing patent portfolio, planned university collaborations, and compliance-driven product development. It aims to convert traditional agricultural resources into higher-value consumer goods by integrating biotechnology, standardized production, and brand building, with planned expansion into North America, Southeast Asia, and Europe via retail, e-commerce, and cross-border channels.

Market Overview

• Total addressable market: China’s healthcare industry reached approximately RMB 11.5–12 trillion in 2024.
• Market growth: Year-over-year growth of about 9%–10% in 2024.
• Market position: Positions itself as a pioneer in “medicinal-food homologous” biofermented cinnamon nutritional wines.
• Key competitors: Not disclosed; competition expected across health beverages, functional foods, and wellness categories.
• Industry trends: Aging population (silver economy), AI-enabled bio-manufacturing, shift from treatment to prevention, and globalization of Chinese health innovations.

Operational Metrics

• Customers: Not disclosed
• Locations: Headquarters in Beijing; principal operations in Mainland China
• Geographic presence: China-based operations with planned expansion to North America, Southeast Asia, and Europe
• Partnerships: Plans for joint laboratories with six universities and research institutions
• Raw material base: 20,000+ mu (approx. 1,333 hectares) of cinnamon cultivation bases via partners
• Production capability: Established an automated cinnamon fermented wine line in 2021; ongoing capacity expansion planned
• Employees: 22 full-time employees as of March 12, 2026
• Facilities: ~1,000 sqm leased office space in Beijing
• Regulatory filings: Filing materials submitted to CSRC under the Trial Measures

Financials Highlights

• Revenue (current): Not disclosed

IPO Structure

• Issuer: Chungui International BioTech Group Co., Ltd.
• Filing date: March 12, 2026
• Proposed ticker: CQFT
• Exchange: Nasdaq Capital Market
• Price range: $5.00 per share (expected)
• Offering size: $15,000,000 (3,000,000 shares at $5.00)
• Shares offered: 3,000,000 Ordinary Shares
• Use of proceeds: Capacity expansion and supply chain (15%); efficacy R&D and compliance (20%); global brand and marketing (15%); channel expansion and retail (10%); corporate operations (10%); IP and compliance (5%); strategic M&A and asset integration (15%); globalization and international expansion (10%).

Original SEC Filing: Chungui International BioTech Group Co., Ltd. - F-1 - Mar. 12, 2026